A pilot crossover trial reported that MedDiet for 6 weeks significantly reduced hepatic steatosis (−39%) compared to subjects that undertook a low fat-high carbohydrate diet (−7%), and it also improved insulin sensitivity even without weight loss in individuals with insulin resistance and NAFLD [32]. This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.